Home / Biosimilars / General / Biosimilars applications under review by EMA – July 2020

Biosimilars applications under review by EMA – July 2020 Posted 10/07/2020

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of biosimilars is based on an abbreviated registration process, which allows biosimilars manufacturers to provide a reduced package of information compared to originator drugs, provided they can prove ‘similarity’ to the originator or reference drug.

All medicines for human and animal use derived from biotechnology and other high-tech processes (including biosimilars) must be approved via the centralized EMA procedure. EMA has both general and product specific guidelines giving information on the requirements for biosimilar applications submitted to EMA [1].

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP) released on 8 June 2020, the agency is reviewing 16 biosimilar applications.

One application is for the immunosuppressant adalimumab, six are for the cancer treatment bevacizumab, one is for the hormone used to treat low blood sugar glucagon, one is for the manufactured insulin product insulin aspart and one is for human insulin (rDNA) – both are for the diabetes treatment, two are for pegfilgrastim, which is used to stimulate neutrophil production in patients undergoing chemotherapy, three are for the osteoporosis treatment teriparatide, and one is for the cancer treatment trastuzumab, see Table 1.

Table 1: Biosimilars under review by EMA*

Common name

Therapeutic area

Number of applications

EMA approved originator(s)

Originator company(ies)

Adalimumab

Immunosuppressant

1

Humira

AbbVie

Bevacizumab

Antineoplastic medicine (anticancer)

6

Avastin

Roche

Glucagon

Pancreatic hormones

1

Baqsimi

Eli Lilly

Insulin aspart

Diabetes

1

NovoLog

Novo Nordisk

Insulin human (rDNA)

Diabetes

1

Actrapid

Mixtard

Protaphane

Insulatard

Actraphane

Insuman

Novo Nordisk

Novo Nordisk

Novo Nordisk

Novo Nordisk

Novo Nordisk

Novo Nordisk

Pegfilgrastim

Immunostimulant (neutropenia)

2

Neulasta

Amgen

Teriparatide

Calcium homeostasis

3

Forteo/Forsteo

Eli Lilly

Trastuzumab

Antineoplastic medicine (anticancer)

1

Herceptin

Roche

Total

 

16

   

*Data collected on 30 June 2020.
Source: EMA.

There are already biosimilars available on the European market to all these products, excluding glucagon, insulin aspart and insulin human (rDNA) [2].

The CHMP has recently recommended approval of the trastuzumab biosimilar Zercepac, which is manufactured by China-based drugmaker Henlius [3].

Related article
Biosimilars applications under review by EMA – January 2020

References
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jul 10]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jul 10]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
3. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of trastuzumab biosimilar Zercepac [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jul 10]. Available from: www.gabionline.net/Biosimilars/News/EMA-recommends-approval-of-trastuzumab-biosimilar-Zercepac

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more